ATE551325T1 - Therapeutische morpholino-substituierte verbindungen - Google Patents

Therapeutische morpholino-substituierte verbindungen

Info

Publication number: ATE551325T1
Authority: AT; Austria
Prior art keywords: kinase; diseases; compounds; morpholino; conditions
Prior art date: 2000-01-24

Application number

AT07009194T

Other languages

English (en)

Inventor

Alan D Robertson

Shaun Jackson

Vijaya Kenche

Cindy Yaip

Hishani Parbaharan

Phil Thompson

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-24

Filing date

2001-01-24

Publication date

2012-04-15

2001-01-24 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE551325T1 publication Critical patent/ATE551325T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 4
230000001225 therapeutic effect Effects 0.000 title 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 3
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 3
150000003906 phosphoinositides Chemical class 0.000 abstract 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
208000007536 Thrombosis Diseases 0.000 abstract 2
230000015572 biosynthetic process Effects 0.000 abstract 2
208000027866 inflammatory disease Diseases 0.000 abstract 2
208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
206010002388 Angina unstable Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010011086 Coronary artery occlusion Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
208000032612 Glial tumor Diseases 0.000 abstract 1
206010018338 Glioma Diseases 0.000 abstract 1
-1 Morpholino-substituted pyridopyrimidine Chemical class 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
206010041067 Small cell lung cancer Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
208000007814 Unstable Angina Diseases 0.000 abstract 1
206010000891 acute myocardial infarction Diseases 0.000 abstract 1
230000002785 anti-thrombosis Effects 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
230000001363 autoimmune Effects 0.000 abstract 1
230000017531 blood circulation Effects 0.000 abstract 1
206010006451 bronchitis Diseases 0.000 abstract 1
230000003915 cell function Effects 0.000 abstract 1
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
210000000265 leukocyte Anatomy 0.000 abstract 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1
208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/64—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with oxygen atoms directly attached in position 8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Oncology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Pyrane Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

AT07009194T 2000-01-24 2001-01-24 Therapeutische morpholino-substituierte verbindungen ATE551325T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17735100P	2000-01-24	2000-01-24
US22582600P	2000-08-17	2000-08-17

Publications (1)

Publication Number	Publication Date
ATE551325T1 true ATE551325T1 (de)	2012-04-15

Family

ID=26873182

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT01902568T ATE363471T1 (de)	2000-01-24	2001-01-24	Durch einen morpholinrest substituierte therapeutische verbindungen
AT07009194T ATE551325T1 (de)	2000-01-24	2001-01-24	Therapeutische morpholino-substituierte verbindungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT01902568T ATE363471T1 (de)	2000-01-24	2001-01-24	Durch einen morpholinrest substituierte therapeutische verbindungen

Country Status (14)

Country	Link
US (4)	US6977255B2 (de)
EP (2)	EP1257537B1 (de)
JP (1)	JP4820518B2 (de)
CN (3)	CN1891693A (de)
AT (2)	ATE363471T1 (de)
AU (2)	AU2001230426C1 (de)
CA (1)	CA2398163C (de)
CY (1)	CY1108023T1 (de)
DE (1)	DE60128655T2 (de)
DK (1)	DK1257537T3 (de)
ES (1)	ES2286093T3 (de)
NZ (1)	NZ520300A (de)
PT (1)	PT1257537E (de)
WO (1)	WO2001053266A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60144277D1 (de)	2000-04-25	2011-05-05	Icos Corp	Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
GB0119863D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0119865D0 (en) *	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB2405870B (en) *	2001-08-14	2005-07-06	Cancer Rec Tech Ltd	DNA-PK inhibitors
CN1551766A (zh) *	2001-09-05	2004-12-01	��ʽ��	淋巴细胞活化抑制剂和自身免疫性疾病治疗剂
US7049313B2 (en)	2002-02-25	2006-05-23	Kudos Pharmaceuticals Ltd.	ATM inhibitors
EP2311818B1 (de) *	2002-02-28	2013-01-16	Novartis AG	Kombination aus einem 5-phenylthiazolderivat als PI3-Kinasehemmer und eine entzündungshemmender, bronchodilatatorische oder antihistaminischen Verbindung
AR038703A1 (es)	2002-02-28	2005-01-26	Novartis Ag	Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
EP1537102A4 (de) *	2002-08-16	2010-12-08	Astrazeneca Ab	Inhibitoren von phosphoinositid-3-kinase beta
CN101260104A (zh) *	2002-08-16	2008-09-10	阿斯利康(瑞典)有限公司	抑制磷酸肌醇3-激酶β
PL382706A1 (pl)	2002-08-26	2007-11-26	Takeda Pharmaceutical Company Limited	Związek modulujący receptor wapnia i jego zastosowanie
BR0316386A (pt)	2002-12-06	2005-09-27	Warner Lambert Co	Benzoxazin-3-onas e seus derivados como inibidores de p13k
GB0305152D0 (en) *	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
WO2004089925A1 (en) *	2003-04-03	2004-10-21	Semafore Pharmaceuticals, Inc.	Pi-3 kinase inhibitor prodrugs
US7547794B2 (en)	2003-04-03	2009-06-16	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
US20040259926A1 (en) *	2003-06-05	2004-12-23	Bruendl Michelle M.	3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
MXPA05013210A (es) *	2003-06-05	2006-03-09	Warner Lambert Co	Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
WO2004108709A1 (en) *	2003-06-05	2004-12-16	Warner-Lambert Company Llc	Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents
KR20060066722A (ko)	2003-08-13	2006-06-16	쿠도스 파마슈티칼스 리미티드	아미노피론 및 ａｔｍ억제제로서의 이의 용도
BRPI0414171A (pt) *	2003-09-04	2006-10-31	Warner Lambert Co	benzo[b]tiofenos halossubstituìdos com atividade inibidora de pi3k como agentes terapêuticos
ATE365732T1 (de) *	2003-10-31	2007-07-15	Warner Lambert Co	Pyrimidine als inhibitoren von phosphoinositid-3- kinasen (pi3k)
AU2005228845A1 (en) *	2004-01-26	2005-10-13	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
LT2612862T (lt)	2004-05-13	2017-01-25	Icos Corporation	Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
CN1300163C (zh) *	2004-06-23	2007-02-14	南京大学	3－羟基色原酮糖苷及其制法和用途
RU2408596C2 (ru)	2004-09-20	2011-01-10	Кудос Фармасьютикалс Лимитед	Ингибиторы днк-пк
JP2008529995A (ja)	2005-02-09	2008-08-07	クドスファーマシューティカルズリミテッド	Ａｔｍ阻害剤
AR054438A1 (es)	2005-04-15	2007-06-27	Kudos Pharm Ltd	Inhibidores de adn -pk
WO2007127366A2 (en)	2006-04-25	2007-11-08	Targegen, Inc.	Kinase inhibitors and methods of use thereof
JP5415942B2 (ja) *	2006-06-22	2014-02-12	プラナバイオテクノロジーリミティッド	処置の方法およびその処置に有用な薬剤
WO2008102932A1 (en) *	2007-02-21	2008-08-28	Biobud Co., Ltd.	Compositions for treating hyperproliferative vascular disorders and cancers
EP2157092A4 (de)	2007-04-11	2011-04-13	Ajinomoto Kk	Mittel zur behandlung von diabetes
EP2154965A4 (de) *	2007-05-29	2011-08-17	Glaxosmithkline Llc	Naphthyridinderivate als p13-kinasehemmer
EP2170338A2 (de) *	2007-07-06	2010-04-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Dna-pkcs zur modulierung von energieregulation und gehirnfunktion
JP2011510071A (ja) *	2008-01-25	2011-03-31	アストラゼネカアクチボラグ	鏡像異性的に純粋な（−）２−［１−（７−メチル−２−（モルホリン−４−イル）−４−オキソ−４Ｈ−ピリド［１，２−ａ］ピリミジン−９−イル）エチルアミノ］安息香酸、医学的療法における該物質の使用、および該物質を含む薬学的組成物−０２６
EP2262366A4 (de) *	2008-04-18	2012-02-22	Shenogen Pharma Group Ltd	Verbindungen und verfahren zur behandlung östrogenrezeptor-vermittelter erkrankungen
CA2738794C (en)	2008-09-29	2016-01-05	Sirtris Pharmaceuticals, Inc.	Chromenone analogs as sirtuin modulators
US8110578B2 (en) *	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
KR20170060179A (ko)	2008-11-13	2017-05-31	길리아드 칼리스토가 엘엘씨	혈액 종양에 대한 요법
PL2448940T3 (pl)	2009-07-02	2014-10-31	Sanofi Sa	Pochodne 6,7,8,9-tetrahydro-pirymido{1,2-a} pirymidyn-4-onu, ich wytwarzanie i zastosowanie farmaceutyczne
KR101745028B1 (ko)	2009-07-02	2017-06-08	사노피	신규 ２,３-디히드로-１ｈ-이미다조（１,２-ａ）피리미딘-５-온 유도체, 그의 제조법 및 그의 제약 용도
AR077628A1 (es)	2009-07-02	2011-09-14	Sanofi Aventis	Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb)
PE20120640A1 (es)	2009-07-02	2012-06-09	Sanofi Sa	Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
CA2768843A1 (en)	2009-07-21	2011-01-27	Gilead Calistoga Llc	Treatment of liver disorders with pi3k inhibitors
US8399460B2 (en)	2009-10-27	2013-03-19	Astrazeneca Ab	Chromenone derivatives
IT1403156B1 (it)	2010-12-01	2013-10-04	Università Degli Studi Di Torino	Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
FR2969613B1 (fr) *	2010-12-23	2013-02-08	Sanofi Aventis	Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
FR2969612B1 (fr) *	2010-12-23	2013-02-08	Sanofi Aventis	Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique
PT2655375E (pt)	2010-12-23	2015-03-02	Sanofi Sa	Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
ES2612492T3 (es)	2010-12-28	2017-05-17	Sanofi	Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB)
EP2808322B1 (de)	2012-01-26	2017-08-23	Daiichi Sankyo Company, Limited	Chromonderivate mit osteogeneseförderungswirkung
EP3406252B1 (de)	2012-02-10	2020-05-13	PTC Therapeutics, Inc.	Verbindungen zur behandlung von spinaler muskelatrophie
US9371336B2 (en)	2012-03-01	2016-06-21	Ptc Therapeutics, Inc.	Compounds for treating spinal muscular atrophy
ES2848273T3 (es)	2012-03-05	2021-08-06	Gilead Calistoga Llc	Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
EP2828247B1 (de)	2012-03-23	2019-01-16	PTC Therapeutics, Inc.	4h-chromen-4-onderivate zur behandlung von spinaler muskelatrophie
ITMI20120514A1 (it) *	2012-03-29	2013-09-30	Cnr Consiglio Naz Delle Ric Erche	Agente terapeutico per il trattamento dei vasi sanguigni
FR2992314B1 (fr)	2012-06-22	2015-10-16	Sanofi Sa	Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
WO2015105657A1 (en) *	2013-12-19	2015-07-16	Ptc Therapeutics, Inc.	Methods for modulating the amount of rna transcripts
JP2017500319A (ja)	2013-12-20	2017-01-05	ギリアードカリストガエルエルシー	（ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
EP3083630B1 (de)	2013-12-20	2019-08-21	Gilead Calistoga LLC	Prozessverfahren für phosphatidylinositol-3-kinase-hemmer
US11021467B2 (en)	2014-06-13	2021-06-01	Gilead Sciences, Inc.	Phosphatidylinositol 3-kinase inhibitors
EP3298017B1 (de) *	2015-05-20	2019-08-14	H. Hoffnabb-La Roche Ag	Verbindungen zur behandlung von spinaler muskelatrophie
EP3310169B1 (de)	2015-05-30	2023-05-17	PTC Therapeutics, Inc.	Verfahren zur modulation von rna-spleissen
CA3119019C (en)	2015-12-10	2024-06-11	Ptc Therapeutics, Inc.	Compounds and methods for treating huntington's disease
US11129824B2 (en) *	2015-12-17	2021-09-28	Biokine Therapeutics Ltd.	Small molecules for inhibiting chemokine activity and/or cancer cells growth
US10646465B2 (en)	2015-12-17	2020-05-12	Biokine Therapeutics Ltd.	Small molecules against cancer
US11091483B2 (en) *	2016-08-12	2021-08-17	Madera Therapeutics, LLC	Protein kinase regulators
JP2019535789A (ja)	2016-11-28	2019-12-12	ピーティーシーセラピューティクス，インコーポレーテッド	Ｒｎａスプライシングを調節する方法
WO2018140730A1 (en)	2017-01-27	2018-08-02	Signalrx Pharmaceuticals, Inc.	Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
EP4151627A1 (de)	2017-06-05	2023-03-22	PTC Therapeutics, Inc.	Verbindungen zur behandlung von morbus huntington
CN111372611A (zh)	2017-06-14	2020-07-03	Ptc医疗公司	修饰rna剪接的方法
CN111182898B (zh)	2017-06-28	2024-04-16	Ptc医疗公司	用于治疗亨廷顿氏病的方法
CN111163838B (zh)	2017-06-28	2023-03-28	Ptc医疗公司	用于治疗亨廷顿氏病的方法
BR112020019373A2 (pt)	2018-03-27	2020-12-29	Ptc Therapeutics, Inc.	Compostos para o tratamento da doença de hutington
KR20210038845A (ko)	2018-06-27	2021-04-08	피티씨 테라퓨틱스, 인크.	헌팅턴병 치료를 위한 헤테로아릴 화합물
IL279688B2 (en)	2018-06-27	2025-01-01	Ptc Therapeutics Inc	Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en)	2018-06-27	2020-01-02	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating huntington's disease
CN109748914B (zh) *	2018-12-29	2021-05-25	上海珂臻医药科技有限公司	吡啶并嘧啶类化合物及其应用
CA3139821A1 (en)	2019-05-13	2020-11-19	Ptc Therapeutics, Inc.	Compounds for treating huntington's disease
CA3090315C (en)	2019-05-15	2023-09-19	Biokine Therapeutics Ltd.	8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death
AR121719A1 (es)	2020-04-03	2022-06-29	Petra Pharma Corp	Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CN111533721B (zh) *	2020-05-15	2022-04-26	浙江大学	苯并吡喃酮或喹啉酮类化合物及其应用
WO2021247859A1 (en) *	2020-06-03	2021-12-09	Yumanity Therapeutics, Inc.	Pyridopyrimidines and methods of their use
WO2022082030A2 (en)	2020-10-15	2022-04-21	Gritstone Bio, Inc.	Antigen-binding proteins and related methods of use
WO2022155503A1 (en)	2021-01-14	2022-07-21	Gritstone Bio, Inc.	Multi-specific antibodies and methods of use
CN117615763A (zh) *	2021-02-01	2024-02-27	健道生物医药有限公司	磷酸肌醇3激酶β抑制剂及其组合物和制备方法
CA3217937A1 (en)	2021-05-03	2022-11-10	Erin Danielle ANDERSON	Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2023013987A (es)	2021-05-27	2024-02-12	Petra Pharma Corp	Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
TW202329930A (zh)	2021-09-30	2023-08-01	美商佩特拉製藥公司	用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
EP4412606A4 (de) *	2021-10-07	2025-09-24	Relay Therapeutics Inc	Pi3k-alpha-inhibitoren und verfahren zur verwendung davon
AU2024406047A1 (en) *	2023-12-19	2026-07-16	Merck Sharp & Dohme Llc	Agonists of trem2 activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS604170A (ja) *	1983-06-21	1985-01-10	Nippon Shinyaku Co Ltd	キノロン誘導体
US5703075A (en) *	1988-12-21	1997-12-30	Pharmacia & Upjohn Company	Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
EP0459983A1 (de) *	1988-12-21	1991-12-11	PHARMACIA & UPJOHN COMPANY	Antiatherosklerotische und antithrombotische 1-benzopyran-4-one und 2-amino-1,3-benzoxazin-4-one
ATE158288T1 (de)	1990-06-20	1997-10-15	Upjohn Co	Antiatherosklerotische und antithrombotische 1- benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on- derivate

2001
- 2001-01-24 AT AT01902568T patent/ATE363471T1/de active
- 2001-01-24 CN CNA200610084723XA patent/CN1891693A/zh active Pending
- 2001-01-24 US US10/181,485 patent/US6977255B2/en not_active Expired - Fee Related
- 2001-01-24 DK DK01902568T patent/DK1257537T3/da active
- 2001-01-24 EP EP01902568A patent/EP1257537B1/de not_active Expired - Lifetime
- 2001-01-24 AU AU2001230426A patent/AU2001230426C1/en not_active Ceased
- 2001-01-24 AT AT07009194T patent/ATE551325T1/de active
- 2001-01-24 CN CNA2006100847155A patent/CN1891699A/zh active Pending
- 2001-01-24 JP JP2001553268A patent/JP4820518B2/ja not_active Expired - Fee Related
- 2001-01-24 EP EP07009194A patent/EP1857443B1/de not_active Expired - Lifetime
- 2001-01-24 DE DE60128655T patent/DE60128655T2/de not_active Expired - Lifetime
- 2001-01-24 AU AU3042601A patent/AU3042601A/xx active Pending
- 2001-01-24 CN CNB018067522A patent/CN1263743C/zh not_active Expired - Fee Related
- 2001-01-24 NZ NZ520300A patent/NZ520300A/en not_active IP Right Cessation
- 2001-01-24 PT PT01902568T patent/PT1257537E/pt unknown
- 2001-01-24 WO PCT/IB2001/000079 patent/WO2001053266A1/en not_active Ceased
- 2001-01-24 CA CA2398163A patent/CA2398163C/en not_active Expired - Fee Related
- 2001-01-24 ES ES01902568T patent/ES2286093T3/es not_active Expired - Lifetime
2004
- 2004-10-12 US US10/961,062 patent/US7405211B2/en not_active Expired - Fee Related
2007
- 2007-07-20 CY CY20071100971T patent/CY1108023T1/el unknown
2008
- 2008-01-24 US US12/019,061 patent/US7572791B2/en not_active Expired - Fee Related
- 2008-05-06 US US12/115,563 patent/US20080312233A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT1257537E (pt)	2007-08-03
DE60128655T2 (de)	2008-02-07
JP4820518B2 (ja)	2011-11-24
US6977255B2 (en)	2005-12-20
DK1257537T3 (da)	2007-10-01
JP2003530318A (ja)	2003-10-14
CY1108023T1 (el)	2013-09-04
DE60128655D1 (de)	2007-07-12
US20080312233A1 (en)	2008-12-18
EP1857443A2 (de)	2007-11-21
EP1857443B1 (de)	2012-03-28
CN1263743C (zh)	2006-07-12
HK1115378A1 (en)	2008-11-28
HK1051187A1 (en)	2003-07-25
US20080206312A1 (en)	2008-08-28
AU3042601A (en)	2001-07-31
EP1257537A4 (de)	2003-04-23
US7405211B2 (en)	2008-07-29
US20030216389A1 (en)	2003-11-20
EP1857443A3 (de)	2007-12-26
AU2001230426B2 (en)	2005-12-01
CA2398163C (en)	2011-02-22
CN1891699A (zh)	2007-01-10
CA2398163A1 (en)	2001-07-26
EP1257537A1 (de)	2002-11-20
CN1891693A (zh)	2007-01-10
CN1418195A (zh)	2003-05-14
NZ520300A (en)	2004-05-28
US20050085471A1 (en)	2005-04-21
ES2286093T3 (es)	2007-12-01
ATE363471T1 (de)	2007-06-15
WO2001053266A1 (en)	2001-07-26
EP1257537B1 (de)	2007-05-30
AU2001230426C1 (en)	2006-06-22
US7572791B2 (en)	2009-08-11

Publication	Publication Date	Title
DK1257537T3 (da)	2007-10-01	Terapeutiske morpholino-substituerede forbindelser
Amirkhosravi et al.	2007	The role of tissue factor pathway inhibitor in tumor growth and metastasis
Rak et al.	2004	Contribution of the hemostatic system to angiogenesis in cancer
UA73004C2 (uk)	2005-05-16	Біциклічні гетероцикли та лікувальний засіб на їх основі
KR20100118977A (ko)	2010-11-08	거울상이성질체적으로 순수한 (-) 2-[1-(7-메틸-2-(모르폴린-4-일)-4-옥소-4Ｈ-피리도[1,2-α]피리미딘-9-일)에틸아미노]벤조산, 의학 치료에서의 이의 용도 및 이를 포함하는 약학 조성물-026
JP5351770B2 (ja)	2013-11-27	ビオチンまたはビオチン誘導体との少なくとも１つの共有結合を含む低分子量ヘパリン、これらの作製方法およびそれらの使用。
ATE266007T1 (de)	2004-05-15	Heterocyclische verbindungen als faktor xa inhibitoren
DE69532195D1 (de)	2004-01-08	Benzamidverbindung und ihre medizinische verwendung
ATE516285T1 (de)	2011-07-15	Dihydropyridinonderivate
LV12047A (lv)	1998-05-20	Kondenseti pirimidina atvasinajumi un to lietosana par angiotenzina II antagonistiem
BR0011295A (pt)	2002-05-28	Aril e heteroaril pirazinonas policìclicas substituìdas úteis para inibição seletiva de cascata de coagulação
SE8304737D0 (sv)	1983-09-02	Karbostyrilderivat
PT1082321E (pt)	2005-03-31	Derivados heterociclicos que inibem o factor xa
NO20064295L (no)	2006-09-22	Bruk av metylenamidderivater i kardiovaskulaere lidelser
BR9914893A (pt)	2001-07-17	Cromenona e derivados de cromanona como inibidores de integrina
JP2009528293A5 (de)	2010-04-15
DK1511466T3 (da)	2009-02-16	Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD
ATE289299T1 (de)	2005-03-15	Polyzyclisch aryl und heteroaryl substituierte 4- pyronen verwendbar als selektive hemmung von dem koagulationsprozess
DE60025644D1 (de)	2006-04-06	Hemmer für das 20-hete-produzierende enzym
JPH07507769A (ja)	1995-08-31	Ｘ因子のグリコシル化媒介による阻害
WO2001079155A3 (en)	2002-05-16	Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
Singla et al.	2015	Interplay between Hemostatic Pathways and Cancer Biology in Head and Neck Cancers
CN105085346B (zh)	2017-03-29	含胺基的l-薄荷醇类p2y12受体拮抗剂及其用途
Peterson et al.	2009	Anticoagulation strategies for venous thromboembolism
Fasco et al.	1987	Evidence for a warfarin‐sensitive serum factor that participates in factor x activation by lewis lung tumor cells